Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OncoZenge ABOSTO:ONCOZ +4.03%26 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates OSTO:ONCOZ with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 940 Biotechnology companies, OncoZenge AB ranks worse than 106382.87% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. OncoZenge AB's EBITDA for the
three
months ended in Mar. 2026 was kr-6.80 Mil. OncoZenge AB's Revenue for the
three
months ended in Mar. 2026 was kr0.00 Mil. Therefore, OncoZenge AB's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.
OncoZenge AB (OSTO:ONCOZ) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
OncoZenge AB EBITDA Margin % Related Terms
OncoZenge AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for OncoZenge AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ONCOZ vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, OncoZenge AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoZenge AB EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OncoZenge AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where OncoZenge AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoZenge AB (OSTO:ONCOZ) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on OncoZenge AB and its competitors. According to the industry distribution chart, OncoZenge AB ranks #999999 out of 940 companies in the Biotechnology industry.
Is OncoZenge AB's EBITDA Margin % too high?
OncoZenge AB's current EBITDA Margin % is 0.00%. Based on the distribution chart, OncoZenge AB ranks #999999 out of 940 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, OncoZenge AB has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does OncoZenge AB's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OncoZenge AB ranks #999999 out of 940 companies for EBITDA Margin %. This places OncoZenge AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on OncoZenge AB and its competitors. OncoZenge AB's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoZenge AB stock overvalued right now?
OncoZenge AB (OSTO:ONCOZ) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. OncoZenge AB's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For OncoZenge AB (OSTO:ONCOZ), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.
26GF Score
Get the complete analysis for OSTO:ONCOZ
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ONCOZ has been successfully added to your 
